Redx Pharma Plc (LON:REDX – Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 15 ($0.20) and traded as low as GBX 11.42 ($0.15). Redx Pharma shares last traded at GBX 15 ($0.20), with a volume of 1,420,135 shares traded.
Redx Pharma Stock Performance
The company has a current ratio of 1.11, a quick ratio of 1.93 and a debt-to-equity ratio of 527.00. The firm’s fifty day moving average price is GBX 15 and its 200-day moving average price is GBX 15.14. The company has a market cap of £58.35 million, a P/E ratio of -150.00 and a beta of -0.53.
Redx Pharma Company Profile
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
See Also
- Five stocks we like better than Redx Pharma
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is a Low P/E Ratio and What Does it Tell Investors?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.